REG - GlaxoSK Capital PLC GSK PLC - Publication of Suppl.Prospcts

GSKAnnouncement

03/11/2022 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221103:nRSC2600Fa&default-theme=true

RNS Number : 2600F  GlaxoSmithKline Capital PLC  03 November 2022

 

Issued: 3 November 2022, London UK - LSE Announcement

 

 

GlaxoSmithKline Capital plc Publication of Supplement to the Base Prospectus

 

GlaxoSmithKline Capital plc today announced that the following supplement
dated 3 November 2022 to the base prospectus dated 7 September 2022 has been
approved by the UK Listing Authority and is available for viewing:

GSK plc, GlaxoSmithKline Capital plc, GSK Capital B.V. and GSK Capital K.K.
£20,000,000,000 Euro Medium Term Note Programme

Copies of the supplement to the base prospectus and the documents incorporated
by reference within it have been submitted to the National Storage Mechanism
and will shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

For further information, please contact:

GSK plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

 

Enquiries:

 UK Media enquiries:                   Tim Foley       +44 (0) 20 8047 5564

(London)
 European Analyst/Investor enquiries:  Nick Stone      +44 (0) 7717 618 834

(London)

James Dodwell
+44 (0) 7881 269 066

(London)

BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENT TO THE BASE PROSPECTUS

Please note that the information contained in the supplement to the base
prospectus may be addressed to and/or targeted at persons who are residents of
particular countries (specified in the base prospectus) only and is not
intended for use and should not be relied upon by any person outside these
countries and/or to whom the offer contained in the supplement to the base
prospectus is not addressed. Prior to relying on the information contained in
the supplement to the base prospectus you must ascertain from the supplement
to the base prospectus whether or not you are part of the intended addressees
of the information contained therein.

Your right to access this service is conditional upon complying with the above

About GSK
GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com/company

 GlaxoSmithKline Capital plc

 Registered in England & Wales:

 No.2258699

 Registered Office:

 980 Great West Road

 Brentford, Middlesex

 TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PSPUPGAAGUPPGPW